More Videos
- Is Merck A Drug Bellwether?
- Pfizer's Statin Study: What A Coincidence!
- Sam Waksal: "Moving On Up" To The East Side
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Yoshikami: Investing & the Obama Presidency
- Wall of Shame: Fortress Investment's Wes Edens
- Cramer to Geithner: Let FDIC Chair Keep Her Job
- Lightning Round: Boeing, Medtronic, Agrium and More
- Lightning Round OT: Continental, Amylin Pharma and More
- Sell Block: Cramer's Solution for Mortgage-Backed Paper Mess
- Toll Brothers CEO's Housing Outlook
- Making Money Off M&A
- Your First Move For Friday December 5th
- Citigroup Sells German Arm for $6.7 Billion
- Charts Predict S&P Festive Rally Above 1,000
- BMW's Global Sales Plunge by a Quarter in Nov.
- Pros Say: Job Losses of 425,000; S&P to Fall to 700
- Bleak Jobs Data Forecasts Add to Automakers' Woes
- Euro Stocks Fall Ahead of US Jobs Data
- European Stocks to Open Sharply Lower
- Toshiba to Briefly Halt Chip Output on Weak Demand
- Boeing Mulls Pushing Back Dreamliner Deliveries
Text Size 
 |
AP |
"You continue--day after day--to knock the company at every opportunity. I understand you had a difficult relationship with the CEO before, but you shouldn't hold a grudge against the company for it. A fair reporter like yourself should always be impartial. As a long suffering PFE shareholder, I would appreciate if you FINALLY (the caps are his) said something positive about PFE," he wrote.
Jim, I'm just reporting what's happening in the market. And when shares of the world's biggest drug company continue to hit nearly 11-year lows, even on a day like today when the rest of the sector is rallying, and The Wall Street Journal does an article this week about the PFE [PFE
Loading...
()
] dividend possibly being at risk, that's a story. Executives have said the big dividend (between a six and seven percent yield) is safe, but investors appear to be worried that it might not be.
And then to make matters worse, this morning James Kelly at Goldman Sachs took Pfizer off of the "Americas Conviction List" and added Eli Lilly [LLY
Loading...
()
] to replace it. That's on top of a Cowen and Company upgrade of LLY yesterday.
Kelly is downgrading PFE from Buy to Neutral (Hold) and upgrading LLY to Buy from Neutral. He also eats a little crow in his research note to clients. "Since Pfizer was added to the Americas Buy List on January 4, 2007, the share price has fallen 28.7 percent, versus a 2.9 percent decline in the S&P 500 and a 20.4 percent decline in our coverage universe," Kelly writes.
related content |
But wait, there's more. "Since the shares were added to the Conviction List on October 24, 2007, they have gone down 21.6 percent versus a 9.1 percent decline for the S&P 500, and over the past 12 months, the share price has declined 31.7 percent compared to a 10.5 percent fall for the S&P 500," he adds.
Kelly likes PFE's valuation, although he's dropping his price target from $26 to $22. But he has fundamental issues. "Near-term pipeline products decrease in value and recent safety issues pressure our Chantix and Sutent (a cancer drug) forecasts. Further, the key launches in the base business have begun to deteriorate (notably Sutent, Chantix and now potentially Lyrica), which is important to our view." Lyrica is a drug for nerve pain and fibromyalgia.
GS has done and wants to do more banking for Pfizer and Lilly . It also makes a market in the shares of both companies. And a retired GS Vice-Chairman sits on the PFE Board.
I'm off tomorrow to sit on a drug industry-focused panel at the Investigative Reporters and Editors convention in Miami. And from there, onto the American Diabetes Association meeting in San Francisco. I'll actually be reporting live from ADA on Monday and Tuesday because the once-a-week Byetta data (say that five times fast) from LLY, Amylin [AMLN
Loading...
()
] and Alkermes [ALKS
Loading...
()
] don't come out until Monday night. We're hoping to do a live, First on CNBC interview with Amylin's CEO Dan Bradbury first thing Tuesday morning.
And, oh, Mr. Mooney, I think Pfizer Chairman and CEO Jeff Kindler and I are just fine.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes